Tau Pathology Initiation Zone Identification

Tau Pathology Initiation Zone

Hypothesis

Primary Hypothesis: 4R-tau pathology in PSP initiates in specific brainstem nuclei (particularly the sublaterodorsal nucleus and cholinergic tegmental nuclei) before spreading to subcortical structures and ultimately the cortex in a predictable pattern that correlates with clinical phenotypes.

Secondary Hypotheses:

The specific initiation zone determines whether patients develop PSP (brainstem predilection) vs CBS (cortical predilection)

Functional connectivity patterns facilitate templated propagation along specific neural networks

The presence of specific genetic variants (MAPT H1/H2, GWAS hits) modifies the initiation zone

Open Question Source

This experiment addresses the critical understanding gap identified in the [CBS/PSP Cure Roadmap](/mechanisms/cbs-psp-cure-roadmap) Phase 2:

• "Where does tau initiate and how does it spread through networks?"

Also complements existing experiments:

• [Tau Spreading Network Mapping via Spatial Transcriptomics](/experiments/tau-spreading-network-mapping-psp) (existing experiment 22, focuses on molecular signatures)
• This experiment focuses on anatomical initiation and propagation patterns

Validation Protocol

Study Design

...

Tau Pathology Initiation Zone

Hypothesis

Primary Hypothesis: 4R-tau pathology in PSP initiates in specific brainstem nuclei (particularly the sublaterodorsal nucleus and cholinergic tegmental nuclei) before spreading to subcortical structures and ultimately the cortex in a predictable pattern that correlates with clinical phenotypes.

Secondary Hypotheses:

The specific initiation zone determines whether patients develop PSP (brainstem predilection) vs CBS (cortical predilection)

Functional connectivity patterns facilitate templated propagation along specific neural networks

The presence of specific genetic variants (MAPT H1/H2, GWAS hits) modifies the initiation zone

Open Question Source

This experiment addresses the critical understanding gap identified in the [CBS/PSP Cure Roadmap](/mechanisms/cbs-psp-cure-roadmap) Phase 2:

• "Where does tau initiate and how does it spread through networks?"

Also complements existing experiments:

• [Tau Spreading Network Mapping via Spatial Transcriptomics](/experiments/tau-spreading-network-mapping-psp) (existing experiment 22, focuses on molecular signatures)
• This experiment focuses on anatomical initiation and propagation patterns

Validation Protocol

Study Design

• Type: Multi-center cross-sectional + longitudinal post-mortem and imaging study
• Cohort:
• Early-stage PSP (n=50): PSP-RS, disease duration <3 years
• Early-stage CBS (n=30): Probable CBS, disease duration <3 years
• Advanced PSP (n=30): Disease duration >5 years
• Controls (n=30): Age-matched, no neurodegenerative pathology

Phase 1: Post-Mortem Mapping

Tissue Collection

• Brain regions (systematic sampling):
• Brainstem: Sublaterodorsal nucleus, pedunculopontine nucleus, dorsal raphe, locus coeruleus
• Basal ganglia: Striatum (caudate, putamen), globus pallidus internus/externus, subthalamic nucleus
• Thalamus: Anterior, mediodorsal, pulvinar
• Cortex: Motor (BA4), premotor (BA6), prefrontal (BA9/46), posterior cingulate (BA23)
• Cerebellum: Deep nuclei
• Processing:
• Alternating sections for histology (H&E, silver stain) and biochemistry
• Fresh frozen for protein extraction and spatial proteomics
• RNA preservation for spatial transcriptomics

Assays

AT8 immunohistochemistry (phospho-tau at Ser202/Thr205)

• Semi-quantitative scoring (0-3) in each region
• Automated image analysis for burden quantification

4R-tau specific assays

• RD4 antibody (detects 4R-tau specifically)
• Comparison with 3R+4R antibodies

Spatial proteomics (CODEX or imaging mass cytometry)

• 50+ protein panel including:
• Tau species (total, phosphorylated at multiple sites)
• Neuronal markers (NeuN, synaptophysin)
• Glial markers (Iba1, GFAP)
• Connectivity markers (synaptic proteins)

Functional connectivity modeling

• Human connectome data (HCP) for normative templates
• Model predicted spread patterns based on anatomical connectivity
• Compare with observed patterns

Phase 2: In Vivo Validation

Imaging Sub-Study

• Tau PET (flortaucipir, PI-2620 for 4R specificity when available)
• MRI (T1, DTI for connectivity, SWI for iron)
• Participants: Early-stage PSP (n=30), age-matched controls (n=15)

Protocol

| Scan | Timepoint | Purpose |
|------|-----------|---------|
| Tau PET (FTP) | Baseline, 12mo | Regional tau burden |
| Tau PET (PI-2620) | Baseline | 4R-tau specificity |
| MR T1 | Baseline, 12mo | Volumetric analysis |
| DTI | Baseline, 12mo | Structural connectivity |
| rs-fMRI | Baseline | Functional connectivity |

Modeling Approach

Spread rate estimation: Compare baseline to 12-month tau PET

Network-based spread model: Fit models using human connectome

Prediction of future spread: Validate against longitudinal data

Phase 3: Genetic Modifiers

• Genotyping: MAPT H1/H2 haplotype, GWAS hits for PSP risk
• Analysis: Association between genetic variants and initiation zone location

Expected Outcomes

Primary Outcomes

Initiation zone identification: Brainstem nuclei identified as primary initiation site in >75% of PSP cases

Propagation pattern: Consistent brainstem → basal ganglia → cortex progression documented

Early detection targets: Identify 2-3 brain regions where tau appears first that could serve as early biomarkers

Secondary Outcomes

CBS vs PSP differentiation: Identify distinct initiation zones for CBS vs PSP

Connectivity-based spread: Confirm network connectivity facilitates templated spread

Genetic modification: Identify genetic variants that influence initiation zone

Exploratory Outcomes

Initiation threshold: Determine burden level at which pathology becomes detectable

Regional vulnerability factors: Identify molecular signatures that explain regional susceptibility

Therapeutic implications: Identify intervention windows before cortical spread

Feasibility Assessment

Strengths

• Integration of post-mortem (gold standard for anatomical mapping) with in vivo imaging
• Multi-center collaboration provides adequate case numbers
• Spatial proteomics provides unprecedented resolution
• Longitudinal component enables spread rate estimation

Challenges

• Early-stage post-mortem tissue is rare (short survival)
• Tau PET has limited sensitivity for brainstem tau
• Post-mortem tissue quality varies
• 4R-specific PET tracers still in development

Timeline

| Milestone | Expected Date |
|-----------|---------------|
| Protocol finalization | Month 1-2 |
| Tissue collection (retrospective + prospective) | Month 3-18 |
| Histology and imaging analysis | Month 12-24 |
| In vivo imaging sub-study enrollment | Month 6-18 |
| Longitudinal imaging completion | Month 18-30 |
| Integrated analysis | Month 30-36 |
| Publication | Month 36-42 |

Cost Estimate

| Category | Cost (USD) |
|----------|------------|
| Personnel (2 FTE, 1 PI, 1 biostatistician) | $1,100,000 |
| Post-mortem tissue procurement | $300,000 |
| Histology and immunohistochemistry | $250,000 |
| Spatial proteomics (CODEX) | $400,000 |
| In vivo imaging (PET/MRI) | $350,000 |
| Data analysis and modeling | $200,000 |
| Indirect costs (20%) | $520,000 |
| Total | $3,120,000 |

Cross-Disease Relevance

This experiment provides insights relevant for:

• AD (similar propagation questions)
• Other tauopathies (FTD, CBD)
• Network spread models (applicable to alpha-synuclein, TDP-43)
• Therapeutic development (identify intervention windows)

See Also

• [CBS/PSP Cure Roadmap](/mechanisms/cbs-psp-cure-roadmap)
• [Tau Spreading Network Mapping (Spatial Transcriptomics)](/experiments/tau-spreading-network-mapping-psp)
• [4R-Tau Targeting in PSP/CBS](/experiments/4r-tau-targeting-psp-cbs)
• [Experiment Priority Index](/experiments/experiment-priority-index)
• [Research Gaps](/gaps/rankings)